应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
GRCE GRACE THERAPEUTICS INC
盘前交易 04-28 06:47:13 EDT
2.16
-0.14
-6.09%
盘前
2.11
-0.05
-2.31%
05:57 EDT
最高
2.35
最低
2.10
成交量
105.31万
今开
2.33
昨收
2.30
日振幅
10.87%
总市值
3,342万
流通市值
2,019万
总股本
1,547万
成交额
228.69万
换手率
11.27%
流通股本
934.85万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Grace Therapeutics公司GTX-104药物遭监管点名 涉及浸出物数据、毒理学评估及生产缺陷
美股速递 · 04-24
Grace Therapeutics公司GTX-104药物遭监管点名 涉及浸出物数据、毒理学评估及生产缺陷
Grace Therapeutics宣布STRIVE-ON三期试验结果摘要获选将在2026年美国神经病学学会年会展示
美股速递 · 04-14
Grace Therapeutics宣布STRIVE-ON三期试验结果摘要获选将在2026年美国神经病学学会年会展示
Grace Therapeutics第三季度每股收益为-0.36美元, 低于预估的-0.34美元
财报速递 · 2025-02-13
Grace Therapeutics第三季度每股收益为-0.36美元, 低于预估的-0.34美元
Grace Therapeutics, Inc.2024财年第三财季实现净利润-3.43百万美元,同比减少4.89%
市场透视 · 2024-11-23
Grace Therapeutics, Inc.2024财年第三财季实现净利润-3.43百万美元,同比减少4.89%
加载更多
公司概况
公司名称:
GRACE THERAPEUTICS INC
所属市场:
NASDAQ
上市日期:
--
主营业务:
Grace Therapeutics, Inc.成立于2002年2月1日。他们专注于开发和商业化用于罕见和孤儿疾病的产品,这些产品有可能通过使用他们的新型药物递送技术来改善临床结果。他们寻求将新的专有配方应用于已获批准和上市的药物化合物,以实现增强疗效、更快起效、减少副作用、更方便的药物递送和提高患者依从性。
发行价格:
--
{"stockData":{"symbol":"GRCE","market":"US","secType":"STK","nameCN":"GRACE THERAPEUTICS INC","latestPrice":2.16,"timestamp":1777320000000,"preClose":2.3,"halted":0,"volume":1053126,"hourTrading":{"tag":"盘前","latestPrice":2.11,"preClose":2.16,"latestTime":"05:57 EDT","volume":6497,"amount":14009.7715159,"timestamp":1777370241874,"change":-0.05,"changeRate":-0.023148,"amplitude":0.023148},"delay":0,"changeRate":-0.06086956521739117,"floatShares":9348500,"shares":15474000,"eps":-0.381942,"marketStatus":"盘前交易","change":-0.14,"latestTime":"04-28 06:47:13 EDT","open":2.33,"high":2.35,"low":2.1,"amount":2286898.7046588003,"amplitude":0.108696,"askPrice":2.22,"askSize":1,"bidPrice":2.1,"bidSize":510,"shortable":3,"etf":0,"ttmEps":-0.381942,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777383000000},"marketStatusCode":1,"adr":0,"listingDate":1357534800000,"exchange":"NASDAQ","adjPreClose":2.16,"preHourTrading":{"tag":"盘前","latestPrice":2.11,"preClose":2.16,"latestTime":"05:57 EDT","volume":6497,"amount":14009.7715159,"timestamp":1777370241874,"change":-0.05,"changeRate":-0.023148,"amplitude":0.023148},"postHourTrading":{"tag":"盘后","latestPrice":2.14,"preClose":2.16,"latestTime":"19:36 EDT","volume":4130,"amount":8866.1021,"timestamp":1777332987628,"change":-0.02,"changeRate":-0.009259,"amplitude":0.018519},"volumeRatio":0.41183364253038274,"impliedVol":0.8991,"impliedVolPercentile":0.1364},"requestUrl":"/m/hq/s/GRCE","defaultTab":"news","newsList":[{"id":"1146744826","title":"Grace Therapeutics公司GTX-104药物遭监管点名 涉及浸出物数据、毒理学评估及生产缺陷","url":"https://stock-news.laohu8.com/highlight/detail?id=1146744826","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146744826?lang=zh_cn&edition=full","pubTime":"2026-04-24 01:17","pubTimestamp":1776964647,"startTime":"0","endTime":"0","summary":"美国生物制药公司Grace Therapeutics Inc.近期披露,其核心候选药物GTX-104遭到监管机构审查,涉及多项关键问题。根据公开信息,监管指出的项目包括药物浸出物研究数据、毒理学安全评估报告以及生产环节存在的缺陷。毒理学评估则用于判断药物潜在毒性风险,这两项数据的完整性对药物获批至关重要。此外,生产环节的缺陷可能影响药品质量的一致性与稳定性。此次监管关注点集中在该公司的主打产品GTX-104上,这款药物正处于关键开发阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GRCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165355983","title":"Grace Therapeutics宣布STRIVE-ON三期试验结果摘要获选将在2026年美国神经病学学会年会展示","url":"https://stock-news.laohu8.com/highlight/detail?id=1165355983","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165355983?lang=zh_cn&edition=full","pubTime":"2026-04-14 20:08","pubTimestamp":1776168512,"startTime":"0","endTime":"0","summary":"Grace Therapeutics(股票代码:GRCE)近日宣布,其针对STRIVE-ON三期临床试验结果的研究摘要已获接受,将于2026年美国神经病学学会(AAN)年会上进行正式报告。\n该摘要重点突出了STRIVE-ON试验的关键数据,这项三期临床研究旨在评估公司某在研疗法的有效性与安全性。此次获选在权威学术会议上展示,标志着该临床试验结果获得了神经病学领域的专业认可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRCE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108073478","title":"Grace Therapeutics第三季度每股收益为-0.36美元, 低于预估的-0.34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1108073478","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108073478?lang=zh_cn&edition=full","pubTime":"2025-02-13 21:09","pubTimestamp":1739452160,"startTime":"0","endTime":"0","summary":"Grace Therapeutics第三季度每股收益为-0.36美元, 低于预估的-0.34美元以上内容来自Benzinga Earnings专栏,原文如下:Grace $Therapeutics(LENZ)$ Q3 EPS $(0.36) Vs $(0.34) Estimate","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRCE","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2485982672","title":"Grace Therapeutics, Inc.2024财年第三财季实现净利润-3.43百万美元,同比减少4.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2485982672","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485982672?lang=zh_cn&edition=full","pubTime":"2024-11-23 00:00","pubTimestamp":1732291227,"startTime":"0","endTime":"0","summary":"11月23日,Grace Therapeutics, Inc.公布财报,公告显示公司2024财年第三财季净利润为-3.43百万美元,同比减少4.89%;其中营业收入为0.00美元,每股基本收益为-0.30美元。从资产负债表来看,Grace Therapeutics, Inc.总负债9.22百万美元,其中短期债务0.00美元,资产负债比为7.09,流动比率为6.02。机构评级:截至2024年11月23日,当前有3家机构对Grace Therapeutics, Inc.目标价做出预测,其中目标均价为10.83美元,其中最低目标价为8.00美元,最高目标价为12.50美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000055a24e4853&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000055a24e4853&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GRCE","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gracetx.com","stockEarnings":[{"period":"1week","weight":-0.5294},{"period":"1month","weight":-0.5375},{"period":"3month","weight":-0.4255},{"period":"6month","weight":-0.3099},{"period":"1year","weight":-0.1325},{"period":"ytd","weight":-0.3757}],"compareEarnings":[{"period":"1week","weight":0.0091},{"period":"1month","weight":0.1279},{"period":"3month","weight":0.0283},{"period":"6month","weight":0.0404},{"period":"1year","weight":0.2988},{"period":"ytd","weight":0.0488}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Grace Therapeutics, Inc.成立于2002年2月1日。他们专注于开发和商业化用于罕见和孤儿疾病的产品,这些产品有可能通过使用他们的新型药物递送技术来改善临床结果。他们寻求将新的专有配方应用于已获批准和上市的药物化合物,以实现增强疗效、更快起效、减少副作用、更方便的药物递送和提高患者依从性。","yearOnYearQuotes":[{"month":1,"riseRate":0.538462,"avgChangeRate":0.036577},{"month":2,"riseRate":0.357143,"avgChangeRate":-0.018558},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.04693},{"month":4,"riseRate":0.214286,"avgChangeRate":-0.072307},{"month":5,"riseRate":0.615385,"avgChangeRate":-0.001291},{"month":6,"riseRate":0.538462,"avgChangeRate":0.01107},{"month":7,"riseRate":0.461538,"avgChangeRate":0.148318},{"month":8,"riseRate":0.076923,"avgChangeRate":-0.157111},{"month":9,"riseRate":0.461538,"avgChangeRate":0.081587},{"month":10,"riseRate":0.153846,"avgChangeRate":-0.11872},{"month":11,"riseRate":0.538462,"avgChangeRate":-0.024598},{"month":12,"riseRate":0.769231,"avgChangeRate":0.071767}],"exchange":"NASDAQ","name":"GRACE THERAPEUTICS INC","nameEN":"GRACE THERAPEUTICS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"GRACE THERAPEUTICS INC(GRCE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供GRACE THERAPEUTICS INC(GRCE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"GRACE THERAPEUTICS INC,GRCE,GRACE THERAPEUTICS INC股票,GRACE THERAPEUTICS INC股票老虎,GRACE THERAPEUTICS INC股票老虎国际,GRACE THERAPEUTICS INC行情,GRACE THERAPEUTICS INC股票行情,GRACE THERAPEUTICS INC股价,GRACE THERAPEUTICS INC股市,GRACE THERAPEUTICS INC股票价格,GRACE THERAPEUTICS INC股票交易,GRACE THERAPEUTICS INC股票购买,GRACE THERAPEUTICS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"GRACE THERAPEUTICS INC(GRCE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供GRACE THERAPEUTICS INC(GRCE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}